慢性肾脏疾病和透析中的抗癌药物剂量

IF 2 3区医学 Q2 UROLOGY & NEPHROLOGY

Advances in chronic kidney disease Pub Date : 2022-03-01 DOI:10.1053/j.ackd.2021.12.002

Anushree C. Shirali , Ben Sprangers

{"title":"慢性肾脏疾病和透析中的抗癌药物剂量","authors":"Anushree C. Shirali , Ben Sprangers","doi":"10.1053/j.ackd.2021.12.002","DOIUrl":null,"url":null,"abstract":"<div>Patients with malignancies have a high prevalence of kidney disease and are often treated with antineoplastic agents that undergo kidney metabolism or excretion or clearance via renal replacement therapies. Thus, the dosing of these agents, including classic chemotherapeutic drugs, targeted therapies, and immunotherapy, must take into account patients’ kidney function. In this review, we will discuss the pitfalls of accurate measurement of kidney function and how kidney disease affects both pharmacodynamic and pharmacokinetic properties of drugs. Lastly, we will discuss specific agents and summarize current dosing strategies for use in patients with chronic kidney disease and end-stage kidney disease.</div>","PeriodicalId":7221,"journal":{"name":"Advances in chronic kidney disease","volume":"29 2","pages":"Pages 208-216.e1"},"PeriodicalIF":2.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Cancer Drug Dosing in Chronic Kidney Disease and Dialysis\",\"authors\":\"Anushree C. Shirali , Ben Sprangers\",\"doi\":\"10.1053/j.ackd.2021.12.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>Patients with malignancies have a high prevalence of kidney disease and are often treated with antineoplastic agents that undergo kidney metabolism or excretion or clearance via renal replacement therapies. Thus, the dosing of these agents, including classic chemotherapeutic drugs, targeted therapies, and immunotherapy, must take into account patients’ kidney function. In this review, we will discuss the pitfalls of accurate measurement of kidney function and how kidney disease affects both pharmacodynamic and pharmacokinetic properties of drugs. Lastly, we will discuss specific agents and summarize current dosing strategies for use in patients with chronic kidney disease and end-stage kidney disease.</div>\",\"PeriodicalId\":7221,\"journal\":{\"name\":\"Advances in chronic kidney disease\",\"volume\":\"29 2\",\"pages\":\"Pages 208-216.e1\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in chronic kidney disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1548559521001671\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in chronic kidney disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1548559521001671","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 1

摘要

恶性肿瘤患者肾脏疾病的患病率很高，通常使用抗肿瘤药物进行治疗，这些药物通过肾脏替代疗法进行肾脏代谢或排泄或清除。因此，这些药物的剂量，包括经典化疗药物、靶向治疗和免疫治疗，必须考虑到患者的肾功能。在这篇综述中，我们将讨论准确测量肾功能的缺陷以及肾脏疾病如何影响药物的药效学和药代动力学特性。最后，我们将讨论特定的药物，并总结目前用于慢性肾病和终末期肾病患者的剂量策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Cancer Drug Dosing in Chronic Kidney Disease and Dialysis

查看原文本刊更多论文

Cancer Drug Dosing in Chronic Kidney Disease and Dialysis

Patients with malignancies have a high prevalence of kidney disease and are often treated with antineoplastic agents that undergo kidney metabolism or excretion or clearance via renal replacement therapies. Thus, the dosing of these agents, including classic chemotherapeutic drugs, targeted therapies, and immunotherapy, must take into account patients’ kidney function. In this review, we will discuss the pitfalls of accurate measurement of kidney function and how kidney disease affects both pharmacodynamic and pharmacokinetic properties of drugs. Lastly, we will discuss specific agents and summarize current dosing strategies for use in patients with chronic kidney disease and end-stage kidney disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances in chronic kidney disease 医学-泌尿学与肾脏学

自引率

3.40%

发文量

审稿时长

11.1 weeks

期刊介绍： The purpose of Advances Chronic Kidney Disease is to provide in-depth, scholarly review articles about the care and management of persons with early kidney disease and kidney failure, as well as those at risk for kidney disease. Emphasis is on articles related to the early identification of kidney disease; prevention or delay in progression of kidney disease